Patent intelligence · US
US 10888618
Method of treating cancer
Method of treating cancer
Patent details — US 10888618
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 12, 2021
- Expiration
- Jan 7, 2041
- Applicant
- Intensity Therapeutics, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524
Quick answer
US 10888618 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted Jan 12, 2021. Expires Jan 7, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Intensity Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524, A61K31/192, A61K31/20
More from Intensity Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10888618?
US 10888618 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted Jan 12, 2021. Expires Jan 7, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10888618?
Intensity Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10888618 expire?
Our index shows an expiration date of Jan 7, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.